SA53 MDM2 INHIBITOR

The p53 protein, often called the “Guardian of the Genome,” is a crucial tumor suppressor gene commonly mutated in human cancers. Its role in preventing tumor formation by inducing programmed cell death in response to cellular stress makes it a key target for cancer therapy. The project focuses on advancing SA53 (Selective Activator of p53), a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue.

SA53 works by triggering the body’s natural defense mechanism, p53, which inhibits or blocks a protein called MDM2. MDM2 is the most important factor that regulates or blocks a protein called p53. p53 works by suppressing or “putting the brakes on” the ability of cancers to grow, spread, and resist anti-cancer treatments. The p53 pathway is one of the most important natural defense mechanisms your body has against cancer. p53 activity is normally increased in response to many pro-cancer conditions. However, nearly all cancers find ways to bypass or prevent the activity of p53.

SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care.

Lamassu’s clinical trial will focus on achieving objectives such as determining a safe dosage for future trials, understanding pharmacokinetic profiles, and assessing early signs of effectiveness in treating soft tissue sarcomas and solid tumors with wild-type p53. The main goal is to advance SA53 through trials to offer a potential new and effective treatment option for patients.